ESMO 2025: Bladder cancer highlights

ctDNA-guided adjuvant atezolizumab improves OS in MIBC

ctDNA-guided adjuvant chemo de-escalation reduces toxicity with comparable outcomes in stage III colon cancer

ESMO 2025: Prostate highlights

ESMO 2025: Renal highlights

Sacituzumab tirumotecan improves progression-free and overall survival in EGFR-TKI resistant NSCLC

177Lu-PSMA-617 with androgen deprivation therapy plus ARPI improves PFS for mHSPC

Zongertinib shows high response rates in first-line HER2-mutant advanced NSCLC

Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors

177Lu-PSMA-617 in metastatic castration-resistant prostate cancer shows higher PSA response with lower toxicity

Adjuvant pembrolizumab in resected merkel cell carcinoma shows improved distant metastasis-free survival

Trastuzumab deruxtecan demonstrates advance in treatment for HER2-positive gastric cancer